New daily shot could ease rare hormone disorder

NCT ID NCT04009291

Completed Disease control Sponsor: Ascendis Pharma A/S Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested a daily injection called TransCon PTH in 59 adults with hypoparathyroidism, a condition where the body doesn't make enough parathyroid hormone. Participants were randomly assigned to receive either the drug or a placebo for four weeks, followed by an open-label extension where everyone received the drug. The goal was to see if the injection could safely bring calcium levels back to normal and reduce the need for supplements.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TransCon PTH (a daily injection of parathyroid hormone)
What this could lead to: If successful, this could provide a more effective way to manage hypoparathyroidism, potentially reducing the need for high doses of calcium and vitamin D supplements.
What could go wrong: This is an early-phase trial with only 59 participants, so results may not apply to everyone. The treatment requires daily injections and may not work for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOCRINE SYSTEM DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endocrine system disorder hypoparathyroidism parathyroid gland disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOCRINE SYSTEM DISEASES HYPOPARATHYROIDISM PARATHYROID DISEASES

Contacts and locations

Locations

Ascendis Pharma Investigational Site

Chicago, Illinois, 60637, United States
Ascendis Pharma Investigational Site

Rochester, Minnesota, 55901, United States
Ascendis Pharma Investigational Site

Great Neck, New York, 11021, United States
Ascendis Pharma Investigational Site

New York, New York, 10032, United States
Ascendis Pharma Investigational Site

Philadelphia, Pennsylvania, 19104, United States
Ascendis Pharma Investigational Site

Oakville, Ontario, L6M 1M1, Canada
Ascendis Pharma Investigational Site

Aalborg, 9000, Denmark
Ascendis Pharma Investigational Site

Aarhus, 8200, Denmark
Ascendis Pharma Investigational Site

Copenhagen, 2200, Denmark
Ascendis Pharma Investigational Site

Dresden, 01307, Germany
Ascendis Pharma Investigational Site

Bologna, 40138, Italy
Ascendis Pharma Investigational Site

Milan, 20132, Italy
Ascendis Pharma Investigational Site

Pisa, 56124, Italy
Ascendis Pharma Investigational Site

Rome, 00128, Italy
Ascendis Pharma Investigational Site

Oslo, 0176, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.